If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    0.50 (0.76%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.67m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

UltraDEX advertising launch

10 Oct 2016 07:00

RNS Number : 0358M
Venture Life Group PLC
10 October 2016
 

Venture Life Group plc

("Venture Life" or the "Company")

 

UltraDEX advertising launch

 

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces the launch of the new UltraDEX advertising campaign in the UK.

 

Since the acquisition of the UltraDEX oral care products range in March 2016, the Company has revitalised the brand, creating a fresh identity and a clearer message on all advertising material and packaging. The range is comprised of a daily oral rinse, toothpaste, oral spray and other inter-dental accessories, and achieved revenues of £1.4 million in the first six months of 2016. The Company's Brands business now represents 20% of its total revenue and the Company remains confident in the growth prospects for UltraDEX, in addition to its other brands, having signed three new distribution agreements for UltraDEX since acquiring it in March 2016.

 

The campaign, launching today, will run for two weeks and aims to increase brand awareness and encourage product trial among new users. UltraDEX will feature on approximately 4,000 tube cards on the London Underground, meaning a banner advertisement in every train carriage on every line, as well as cross track posters in 91 Underground stations. In conjunction with this, the Company will run an extensive radio campaign in London and the South East and free UltraDEX samples will be given out at Waterloo, Victoria and Liverpool Street stations. A new website (www.ultradex.co.uk) has also been launched and whilst the overall level of advertising is significant for Venture Life it is in line with budgeted plans. It will also support in-store activity amongst Venture Life's key retail partners such as Boots, Tesco, Sainsbury's and Amazon, as the Company continues to grow the retail presence of the brand.

 

Commenting, Chief Executive Officer of Venture Life, Jerry Randall, said: "The acquisition of UltraDEX has had a big impact on our Brands business and we are expecting it to make a significant contribution towards Group profitability. This campaign is being run initially in the London and South East region as we continue to invest behind the UltraDEX brand and support our retail partners."

 

If any investors would like a sample of the UltraDEX products, please contact Walbrook PR using the contact details below.

 

For further information, please contact:

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

 

James Hunter, Chief Financial Officer

 

 

 

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Freddy Crossley/Peter Steel/Duncan Monteith (Corporate Finance)

 

Tom Salvesen (Corporate Broking)

 

 

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope/Ben Turner

 

 

Walbrook PR

venturelife@walbrookpr.com or +44 (0) 20 7933 8780

Paul McManus/Anna Dunphy

+44 (0) 7980 541 893 / +44 (0) 7876 741 001

 

 

 

About Venture Life (www.venture-life.com)

 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.

 

The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAZDLFBQBFEFBE
Date   Source Headline
8th May 20182:54 pmRNSHolding(s) in Company
30th Apr 20187:00 amRNSUltraDEX update
17th Apr 20187:00 amRNSDirector/PDMR Shareholding
5th Apr 20187:00 amRNSDirector/PDMR Shareholding
27th Mar 20187:00 amRNSDirector/PDMR Shareholding
26th Mar 20187:00 amRNS2018 LTIP and Grant of Options to PDMRs
22nd Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of analyst & investor results briefings
16th Feb 20187:00 amRNSInvestor presentation
13th Feb 20187:00 amRNSCommerical update
31st Jan 20187:00 amRNSTrading update
8th Jan 20187:00 amRNSEuropean Business Awards 'Ones to Watch List'
24th Nov 20177:00 amRNSNew exclusive partner secured in Austrian market
23rd Nov 201711:14 amRNSUK Bond Network presentation
14th Nov 20177:00 amRNSVox Markets
30th Oct 20177:00 amRNSUltraDEX update
10th Oct 20177:00 amRNSHolding(s) in Company
2nd Oct 20177:00 amRNSFDA approval for the US market
21st Sep 20177:00 amRNSHalf-year Report
7th Sep 20177:00 amRNSDistribution partners and Lubatti China update
4th Sep 20177:00 amRNSNotice of Results
7th Aug 20174:24 pmRNSDirector/PDMR Shareholding
19th Jul 20177:00 amRNSDistribution partner for UltraDEX & patent update
12th Jul 20177:00 amRNSTrading update
23rd May 201710:59 amRNSResult of AGM
23rd May 20177:00 amRNSUltraDEX Patent Grants and Distribution Update
18th May 20177:00 amRNSTwo new CE Mark approvals
10th May 20179:00 amRNS'1000 Companies to Inspire Britain' 2017 report
4th May 20177:00 amRNSChange of Adviser
4th May 20177:00 amRNSGrant of Options
25th Apr 20177:00 amRNS2017 Long Term Incentive Plan and Grant of Options
29th Mar 20173:36 pmRNSUK Investor Show attendance
23rd Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSDirectorate Change
1st Feb 20171:08 pmRNSHolding(s) in Company
31st Jan 20174:39 pmRNSInvestor Day presentation now available
26th Jan 20177:00 amRNSTrading update
20th Dec 20167:00 amRNSInvestor evening
29th Nov 20166:06 pmRNSHolding(s) in Company
28th Nov 20167:00 amRNSAppointment of Vox Markets
17th Nov 20167:00 amRNSInvestor evening
14th Nov 20167:00 amRNSTrading update
10th Nov 20167:00 amRNSDirectorate Change
10th Oct 20167:00 amRNSUltraDEX advertising launch
7th Oct 201612:10 pmRNSIssue of Equity
29th Sep 20167:00 amRNS2016 LTIP adopted & Grant of Options
21st Sep 20167:00 amRNSHalf-year Report
21st Sep 20167:00 amRNSAppointment of joint broker
7th Sep 20167:00 amRNSNotice of Results
29th Jul 20167:00 amRNSPre-close trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.